Avista Pharma Solutions Launches as New CDMO
Accuratus Lab Services, a contract analytical testing laboratory, and its principal owner, the private-equity firm, Ampersand Capital Partners, have acquired the chemistry, manufacturing, and controls (CMC) operation of Array Biopharma Inc. The Array CMC operation will be known as Avista Pharma Solutions and be housed in a 50,000-square foot laboratory facility in Longmont, Colorado. Under Accuratus ownership, Avista will continue to support the CMC services requirements of its former parent Array BioPharma while expanding its business with other clients. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small-molecule drugs to treat cancer. Six Phase 3 studies are currently advancing, includingthree cancer drugs: binimetinib (MEK162 /wholly owned), encorafenib (LGX818 / wholly owned) and selumetinib (partnered with AstraZeneca).
Accuratus was formed in July 2014 when ATS Labs of Eagan, Minnesotaacquired Microtest Labs of Agawam, Massachusetts. Accuratus provides GMP and GLP analytical and microbial testing services to the medical device and biopharmaceutical industries as well as manufacturers of EPA-regulated consumer products. The addition of Array's CMC operation sets the course for Accuratus to become a contract development and manufacturing organization (CDMO) in the pharmaceutical industry.
Existing Accuratus locations will continue to deliver services to clients as they have previously while offering the expanded capabilities of the Longmont team and facility of Avista.
Source: Accuratus Lab Services